Paliperidonpalmitaat-d4

Paliperidone palmitate-d4 (9-Hydroxyrisperidone palmitate-d4) is the deuterium labeled Paliperidone palmitate. Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia[1][2][3].

1794685-21-4

9-Hydroxyrisperidone palmitate-d4

12352005

5-HT Receptor; Dopamine Receptor; Isotope-Labeled Compounds

GPCR/G Protein; Neuronal Signaling; Others

Neuroscience-Neuromodulation

Neurological Disease

FC1=CC=C(C(C2CCN(CC2)C([2H])([2H])C([2H])([2H])C3=C(C)N=C(C(CCC4)OC(CCCCCCCCCCCCCCC)=O)N4C3=O)=NO5)C5=C1

C39H53D4FN4O4

668.92

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-A0019AS/

Isotope-Labeled Compounds

No Development Reported